2022
Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension
Stergiou G, Brunström M, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Muxfeldt E, Zhang Y, Mancia G, Kreutz R, Tomaszewski M. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. Journal Of Hypertension 2022, 40: 1847-1858. PMID: 35983870, DOI: 10.1097/hjh.0000000000003240.Peer-Reviewed Original ResearchConceptsAntihypertensive drugsAntihypertensive medicationsBedtime dosingOutcome trialsDrug dosingClinical practiceEfficient medical interventionsHypertension position paperMorning BP surgeNight-time hypertensionAntihypertensive drug therapyAntihypertensive drug treatmentSingle morning doseBlood pressure profileEffective treatment strategiesWorld Hypertension LeagueInternational SocietyAntihypertensive treatmentBedtime administrationBP controlBP surgeMorning doseMorning dosingCardiovascular eventsAdverse prognosis
2009
Is there a role for direct renin inhibitors in chronic kidney disease?
Peixoto AJ, Orias M. Is there a role for direct renin inhibitors in chronic kidney disease? Current Opinion In Nephrology & Hypertension 2009, 18: 397-403. PMID: 19584722, DOI: 10.1097/mnh.0b013e32832e3183.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseBlood pressure controlKidney disease progressionRenin inhibitorsCardiovascular eventsKidney diseaseDisease progressionEffective blood pressure controlPressure controlHard renal endpointsEarly diabetic nephropathyNormal renal functionDirect renin inhibitorRandomized clinical trialsRenal endpointsStudy drugCardiovascular riskDiabetic nephropathyRenal functionRenal injuryImproved survivalClinical trialsAnimal modelsHuman studiesPatients